Conditions on Commercialisation Sample Clauses

Conditions on Commercialisation. The Commercialisation of Project IP must:
Sample 1
AutoNDA by SimpleDocs
Conditions on Commercialisation. The Commercialisation of Project IP must: comply with the terms of the Commercialisation Plan; maximise the national benefits accruing to Australia, including the Australian defence industry; be consistent with the objectives of the Defence CRC Program; comply with all applicable Australian and international export controls, and counter-proliferation and counter-terrorism regulations; and be consistent with this Agreement, including the National Security Requirements. For the purposes of clause 1.65(b), the maximum national benefits accruing to Australia will be deemed to have been delivered where the IPR in Project IP are Commercialised or otherwise made available in a way that results in the enhancement or building of Australia's defence industry capabilities. Where there are no opportunities for Commercialisation within Australia and the Commercialisation of the IPR occurs in a country other than Australia (to the extent permitted by the terms of this Agreement), the IPR must be Commercialised or utilised in such a way that substantial national benefits will accrue to Australia. Loss of Commercialisation rights A Party (Commercialising Party) that has been granted the rights to Commercialise Project IP (or has such rights per force of its ownership of the Project IP) will immediately forfeit its ownership of the Project IP and all Commercialisation rights with respect to such Project IP if it is subject to a Default Event.
Sample 1
Conditions on Commercialisation. The Commercialisation of Project IP must: comply with the terms of the Commercialisation Plan; maximise the national benefits accruing to Australia, including the Australian defence industry; be consistent with the objectives of the Defence CRC Program; comply with all applicable Australian and international export controls, and counter-proliferation and counter-terrorism regulations; and be consistent with this Agreement, including the National Security Requirements. For the purposes of clause 12.1(b), the maximum national benefits accruing to Australia will be deemed to have been delivered where the IPR in Project IP are Commercialised or otherwise made available in a way that results in the enhancement or building of Australia's defence industry capabilities. Where there are no opportunities for Commercialisation within Australia and the Commercialisation of the IPR occurs in a country other than Australia (to the extent permitted by the terms of this Agreement), the IPR must be Commercialised or utilised in such a way that substantial national benefits will accrue to Australia. Loss of Commercialisation rights A Party (Commercialising Party) that has been granted the rights to Commercialise Project IP (or has such rights per force of its ownership of the Project IP) will immediately forfeit its ownership of the Project IP and all Commercialisation rights with respect to such Project IP if it is subject to a Default Event. For the purposes of clause 12.3a, Default Event means any of: a breach by the Commercialising Party of its Participant Agreement that results in its expulsion from the Defence CRC; a breach by the Commercialising Party of the National Security Requirements; the Commercialising Party is subject to any of the events set out in clauses 6.2(b)(xxviii)(xxxv) (inclusive); or the Commercialising Party: fails to Commercialise the Project IP (so as to meet the minimum requirements of the Commercialisation Plan) within two (2) years of the grant of Commercialisation rights or the completion of the Project (whichever is later); and following a meeting with the Company, or if the Company has been wound up or deregistered, with Defence, to review the proposed Commercialisation of the Project IP and to develop strategies to facilitate Commercialisation by the Commercialising Party (and the Commercialising Party must attend such a meeting at the Company’s or Defence’s request), the Commercialising Party fails to Commercialise the Project IP within a...
Sample 1

Related to Conditions on Commercialisation

  • Commercialization Intrexon shall have the right to develop and Commercialize the Reverted Products itself or with one or more Third Parties, and shall have the right, without obligation to Fibrocell, to take any such actions in connection with such activities as Intrexon (or its designee), at its discretion, deems appropriate.

  • General Approach The parties will strive to achieve on-going performance improvement. They will follow a proactive, collaborative and responsive approach to performance management and improvement. Either party may request a meeting at any time. The parties will use their best efforts to meet as soon as possible following a request.

  • Application of General Conditions These General Conditions set forth the terms and conditions generally applicable to the Development Grant Agreement to the extent and subject to any modifications set forth in such agreement.”

  • Clinical Trials The studies, tests and preclinical and clinical trials conducted by or on behalf of, or sponsored by, the Company, or in which the Company has participated, that are described in the Registration Statement, the Time of Sale Disclosure Package or the Prospectus, or the results of which are referred to in the Registration Statement, the Time of Sale Disclosure Package or the Prospectus, were and, if still pending, are being conducted in all material respects in accordance with protocols, procedures and controls pursuant to, where applicable, accepted professional and scientific standards for products or product candidates comparable to those being developed by the Company and all applicable statutes, rules and regulations of the FDA, the EMEA, Health Canada and other comparable drug and medical device (including diagnostic product) regulatory agencies outside of the United States to which they are subject; the descriptions of the results of such studies, tests and trials contained in the Registration Statement, the Time of Sale Disclosure Package or the Prospectus do not contain any misstatement of a material fact or omit a material fact necessary to make such statements not misleading; the Company has no knowledge of any studies, tests or trials not described in the Disclosure Package and the Prospectus the results of which reasonably call into question in any material respect the results of the studies, tests and trials described in the Registration Statement, the Time of Sale Disclosure Package or Prospectus; and the Company has not received any notices or other correspondence from the FDA, EMEA, Health Canada or any other foreign, state or local governmental body exercising comparable authority or any Institutional Review Board or comparable authority requiring or threatening the termination, suspension or material modification of any studies, tests or preclinical or clinical trials conducted by or on behalf of, or sponsored by, the Company or in which the Company has participated, and, to the Company’s knowledge, there are no reasonable grounds for the same. Except as disclosed in the Registration Statement, the Time of Sale Disclosure Package and the Prospectus, there has not been any violation of law or regulation by the Company in its respective product development efforts, submissions or reports to any regulatory authority that could reasonably be expected to require investigation, corrective action or enforcement action.

  • DEVELOPMENT OR ASSISTANCE IN DEVELOPMENT OF SPECIFICATIONS REQUIREMENTS/ STATEMENTS OF WORK Firms and/or individuals that assisted in the development or drafting of the specifications, requirements, statements of work, or solicitation documents contained herein are excluded from competing for this solicitation. This shall not be applicable to firms and/or individuals providing responses to a publicly posted Request for Information (RFI) associated with a solicitation.

  • Completion of Concrete Pours and Emergency Work 24.14.1 Except as provided in this sub-clause an employee shall not work or be required to work in the rain.

  • Placement of DNS probes Probes for measuring DNS parameters shall be placed as near as possible to the DNS resolvers on the networks with the most users across the different geographic regions; care shall be taken not to deploy probes behind high propagation-­‐delay links, such as satellite links.

  • Trials The Ship shall run the following test and trials:

  • Project Implementation 2. The Borrower shall:

  • CHARACTERISTICS OF THE ACADEMY 10) The characteristics of the Academy set down in Section 1(6) of the Academies Act 2010, are that:

Time is Money Join Law Insider Premium to draft better contracts faster.